The purpose of this clinical trial is to evaluate efficacy and safety of once weekly subcutaneous (SC) doses of navepegritide 100 μg/kg compared to placebo (inactive drug) in adolescents aged 12 to 18 years with Achondroplasia. What will be measured is Annualized Growth Velocity after a 52-week treatment period.
Protocol Amendment History
4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2024-12-10; most recent amendment 2026-04-20.